{"id":53874,"date":"2023-02-13T22:03:04","date_gmt":"2023-02-13T21:03:04","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/bitt-provides-update-on-domab-platform-and-cd40-program\/"},"modified":"2023-02-13T22:03:04","modified_gmt":"2023-02-13T21:03:04","slug":"bitt-provides-update-on-domab-platform-and-cd40-program","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/bitt-provides-update-on-domab-platform-and-cd40-program\/","title":{"rendered":"BITT Provides Update on DOMab Platform and CD40 Program"},"content":{"rendered":"
\n

BOSTON–(BUSINESS WIRE)–#tnfr2<\/a>–Boston Immune Technologies and Therapeutics, Inc. (BITT), a privately held developer of novel tumor necrosis factor superfamily receptor (TNFSR) antagonist antibodies, announced today updates on the company\u2019s DOMab\u2122 platform. Two DOMab CD40 antagonists (BITT-CD4D11 and BITT-CD4F10) have completed discovery and optimization and a final candidate is being selected for IND-enabling steps. BITT-CD4D11 and BITT-CD4F10 are being developed for indications in autoimmunity and inflammation including Crohn\u2019s disease, inflammatory bowel disease, psoriasis, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus and Sj\u00f6gren\u2019s syndrome. BIR2101, BITT\u2019s anti-cancer dominant tumor necrosis factor receptor 2 (TNFR2) antagonist and most advanced antibody candidate, has completed IND-enabling steps and an IND filing is anticipated by the end of Q1 2023.\n<\/p>\n

\n\u201cThe development of dominant antibodies to our second TNF superfamily target is a major validation for the DOMab platform,\u201d said Russell LaMontagne, Co-Founder and Chief Executive Officer of BITT. \u201cWe will be presenting preclinical data from both the CD40 and TNFR2 programs at conferences in the first half of 2023.\u201d\n<\/p>\n

\nBITT\u2019s DOMab antibodies create unique surface stabilization of anti-parallel dimers for altering intracellular signaling. For TNF superfamily proliferative pathways (such as TNFR2, TRAIL and HVEM), antagonism causes cell death. For death receptors (such as CD40, CD27 and OX40), antagonism permits cell growth. The technology\u2019s ability to create antibodies that target only rapidly proliferating cells opens the door to TNF superfamily targets that were previously considered undruggable or limited by toxicology.\n<\/p>\n

\nAbout Boston Immune Technologies and Therapeutics
\n
<\/b>Boston Immune Technologies and Therapeutics, Inc. (BITT) is a Boston, MA-based company developing a novel class of antagonist antibodies targeting TNF superfamily receptors for applications in oncology, inflammation, autoimmunity, and infectious disease based on the company\u2019s DOMab\u2122 platform. BITT is initiating clinical trials for BIR2101, its lead candidate, which is a monoclonal antibody that targets tumor necrosis factor receptor 2 (TNFR2). BITT is also developing additional antibodies targeting TNF superfamily receptors for indications in inflammation, oncology and infectious disease. Learn more at: www.bostonimmunetech.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nKarl Schmieder
\n
karl@messaginglab.com<\/a>
(646) 515-3392\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BOSTON–(BUSINESS WIRE)–#tnfr2–Boston Immune Technologies and Therapeutics, Inc. (BITT), a privately held developer of novel tumor necrosis factor superfamily receptor (TNFSR) antagonist antibodies, announced today updates on the company\u2019s DOMab\u2122 platform. Two DOMab CD40 antagonists (BITT-CD4D11 and BITT-CD4F10) have completed discovery and optimization and a final candidate is being selected for IND-enabling steps. BITT-CD4D11 and BITT-CD4F10 … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53874","6":"format-standard","7":"category-industry"},"yoast_head":"\nBITT Provides Update on DOMab Platform and CD40 Program - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/bitt-provides-update-on-domab-platform-and-cd40-program\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BITT Provides Update on DOMab Platform and CD40 Program - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BOSTON–(BUSINESS WIRE)–#tnfr2–Boston Immune Technologies and Therapeutics, Inc. (BITT), a privately held developer of novel tumor necrosis factor superfamily receptor (TNFSR) antagonist antibodies, announced today updates on the company\u2019s DOMab\u2122 platform. Two DOMab CD40 antagonists (BITT-CD4D11 and BITT-CD4F10) have completed discovery and optimization and a final candidate is being selected for IND-enabling steps. BITT-CD4D11 and BITT-CD4F10 ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/bitt-provides-update-on-domab-platform-and-cd40-program\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-13T21:03:04+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bitt-provides-update-on-domab-platform-and-cd40-program\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bitt-provides-update-on-domab-platform-and-cd40-program\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"BITT Provides Update on DOMab Platform and CD40 Program\",\"datePublished\":\"2023-02-13T21:03:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bitt-provides-update-on-domab-platform-and-cd40-program\\\/\"},\"wordCount\":352,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bitt-provides-update-on-domab-platform-and-cd40-program\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bitt-provides-update-on-domab-platform-and-cd40-program\\\/\",\"name\":\"BITT Provides Update on DOMab Platform and CD40 Program - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-02-13T21:03:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bitt-provides-update-on-domab-platform-and-cd40-program\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bitt-provides-update-on-domab-platform-and-cd40-program\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bitt-provides-update-on-domab-platform-and-cd40-program\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BITT Provides Update on DOMab Platform and CD40 Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BITT Provides Update on DOMab Platform and CD40 Program - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/bitt-provides-update-on-domab-platform-and-cd40-program\/","og_locale":"en_US","og_type":"article","og_title":"BITT Provides Update on DOMab Platform and CD40 Program - Pharma Trend","og_description":"BOSTON–(BUSINESS WIRE)–#tnfr2–Boston Immune Technologies and Therapeutics, Inc. (BITT), a privately held developer of novel tumor necrosis factor superfamily receptor (TNFSR) antagonist antibodies, announced today updates on the company\u2019s DOMab\u2122 platform. Two DOMab CD40 antagonists (BITT-CD4D11 and BITT-CD4F10) have completed discovery and optimization and a final candidate is being selected for IND-enabling steps. BITT-CD4D11 and BITT-CD4F10 ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/bitt-provides-update-on-domab-platform-and-cd40-program\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-13T21:03:04+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/bitt-provides-update-on-domab-platform-and-cd40-program\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/bitt-provides-update-on-domab-platform-and-cd40-program\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"BITT Provides Update on DOMab Platform and CD40 Program","datePublished":"2023-02-13T21:03:04+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/bitt-provides-update-on-domab-platform-and-cd40-program\/"},"wordCount":352,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/bitt-provides-update-on-domab-platform-and-cd40-program\/","url":"https:\/\/pharma-trend.com\/en\/bitt-provides-update-on-domab-platform-and-cd40-program\/","name":"BITT Provides Update on DOMab Platform and CD40 Program - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-02-13T21:03:04+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/bitt-provides-update-on-domab-platform-and-cd40-program\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/bitt-provides-update-on-domab-platform-and-cd40-program\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/bitt-provides-update-on-domab-platform-and-cd40-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"BITT Provides Update on DOMab Platform and CD40 Program"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53874","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53874"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53874\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53874"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53874"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53874"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}